Phase II study of interleukin-4 in indolent B-cell non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group …

PH Wiernik, JP Dutcher, X Yao… - Journal of …, 2010 - journals.lww.com
Abstract Recombinant interleukin (IL)-4, 5 μg/kg thrice weekly for 3 weeks followed by a 2-
week rest period (1 cycle) was administered to 32 eligible previously treated B-cell chronic
lymphocytic leukemia (7 patients) or low-grade B-cell lymphoma patients (25 patients). Two
cycles were given before response was evaluated. IL-6 serum levels were evaluated before
therapy in all patients and at 12 weeks on study in 7 patients. None of the chronic
lymphocytic leukemia patients responded. A partial response was observed in 3 lymphoma …